Peptide stacks

• RecoveryWolverine StackBPC-157TB-500The one controlled study of the pair we found is a 2026 rat study.
• Fat lossGH / Body Comp StackTesamorelinIpamorelinTesamorelin alone has FDA approval and Phase 3 data showing 15–18% visceral fat reduction over 26 weeks.
• SleepSleep StackGHRP-2DSIPDSIP has three small human trials from the 1980s–90s, one double-blind with significant improvements in sleep efficiency and latency.
• RecoveryRecovery + SleepBPC-157DSIPZero interaction data.
• Skin & hairSkin StackGHK-CuMatrixyl 3000Topical GHK-Cu has small human studies over 20+ years, including a 1-month biopsy pilot: 7 of 10 volunteers on a copper-peptide cream made more new collagen, against 5 of 10 on vitamin C and 4 of 10 on tretinoin.
• LongevityLongevity StackGHK-CuEpitalonMOTS-CTopical GHK-Cu is the only component with human clinical data.
• Skin & hair· One pre-blended vialGLOWGHK-CuBPC-157TB-500The individual components have been studied.
• Recovery· One pre-blended vialKLOWGHK-CuKPVBPC-157TB-500There is no published study of any four-compound formulation of this kind.
• Fat loss· One pre-blended vialTesa / Ipa BlendTesamorelinIpamorelinThe two compounds separately are the best-documented pair in this file: tesamorelin has FDA approval and Phase 3 visceral-fat data, ipamorelin has Phase 2 studies of selective GH release and remains a 503B Category 2 substance.
• Skin & hair· One pre-blended vialGHK-Cu / KPVGHK-CuKPVNeither component has human data by injection.
• MuscleThe GH StackCJC-1295 (no DAC)IpamorelinThis is the one combination multiple sources call mechanistically sound rather than merely non-conflicting, and that reasoning is legitimate.
• GutGut StackBPC-157KPVZero interaction data, and zero human data for KPV by any route.
• ImmuneImmune StackThymosin alpha-1KPVThymosin alpha-1 alone has genuine trial data, including positive results in chronic hepatitis B and a 1,089-patient Phase 3 in sepsis that was negative.
• CognitionSemax + SelankSemaxSelankNo clinical trial has tested Semax and Selank as a combination protocol in humans.
• SleepDSIP + EpitalonDSIPEpitalonDSIP has three small human trials from the 1980s–90s, one double-blind.
• Fat loss· One pre-blended vialCagriSemaCagrilintideSemaglutideREDEFINE 1 (68 weeks, n=3,417, without diabetes): −20.4% versus −3.0% on placebo under the treatment-policy estimand, −22.7% under ideal adherence; 91.9% reached at least 5% loss.
• Fat lossSemaglutide: oral ↔ injectableSemaglutideThis comes from the Wegovy prescribing information, revised June 2026, not from a vendor page and not from community practice.
• Fat lossGLP-1 + muscle preservationSemaglutideCJC-1295 (no DAC)IpamorelinBPC-157The clinical evidence for these compounds in combination with semaglutide or tirzepatide is essentially zero.
• Fat lossAdvanced RecompRetatrutideCJC-1295 (no DAC)IpamorelinNo published human trial has tested retatrutide with CJC-1295 and ipamorelin together.
• Fat lossBimagrumab + semaglutideBimagrumabSemaglutideBELIEVE, Phase 2, NCT05616013, n=507, 48 weeks with an open-label extension to week 72.
• LibidoPT-141 + a PDE5 inhibitorPT-141Palatin announced an open-label dose-escalation Phase 2 of roughly 50 participants, with topline anticipated at the end of 2024.

The Playbook is explicit that stacking is the least evidence-based part of this field, and that the popular online protocols were assembled by people with something to sell. So every stack here leads with its evidence verdict rather than burying it.